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ttp://dx.doi.org/10.1016/j.ajpath.2013.12.020Monocyte/macrophage polarization in skeletal muscle regeneration is ill deﬁned. We used CD11b-
diphtheria toxin receptor transgenic mice to transiently deplete monocytes/macrophages at multiple
stages before and after muscle injury induced by cardiotoxin. Fat accumulation within regenerated
muscle was maximal when ablation occurred at the same time as cardiotoxin-induced injury. Early
ablation (day 1 after cardiotoxin) resulted in the smallest regenerated myoﬁber size together with
increased residual necrotic myoﬁbers and fat accumulation. However, muscle regeneration after late
(day 4) ablation was similar to controls. Levels of inﬂammatory cells in injured muscle following early
ablation and associated with impaired muscle regeneration were determined by ﬂow cytometry. Delayed,
but exaggerated, monocyte [CD11bþ(CD90/B220/CD49b/NK1.1/Ly6G)(F4/80/I-Ab/CD11c)Ly6Cþ/]
accumulation occurred; interestingly, Ly6Cþ and Ly6C monocytes were present concurrently in ablated
animals and control mice. In addition to monocytes, proinﬂammatory, Ly6Cþ macrophage accumulation
following early ablation was delayed compared to controls. In both groups, CD11bþF4/80þ cells
exhibited minimal expression of the M2 markers CD206 and CD301. Nevertheless, early ablation delayed
and decreased the transient accumulation of CD11bþF4/80þLy6CCD301 macrophages; in control
animals, the later tissue accumulation of these cells appeared to correspond to that of anti-
inﬂammatory macrophages, determined by cytokine production and arginase activity. In summary,
impairments in muscle regeneration were associated with exaggerated monocyte recruitment and
reduced Ly6C macrophages; the switch of macrophage/monocyte subsets is critical to muscle
regeneration. (Am J Pathol 2014, 184: 1167e1184; http://dx.doi.org/10.1016/j.ajpath.2013.12.020)Supported by NIH NHLBI grants R01 HL074236 and F30 HL110743,
NIH NCATS grant UL1TR001120, NIH NCI grant P30 CA054174 [to the
Core Flow Cytometry Facility (Cancer Therapy & Research Center) of the
University of Texas Health Science Center, San Antonio] and Veterans
Administration Merit Review grant 1I01BX001186.
Disclosures: None declared.Skeletal muscle has a remarkable capacity for regeneration
with a complex injury/repair process that includes inﬂam-
mation, myoﬁber regeneration, and angiogenesis. The
careful orchestration of inﬂammatory cells and resident
muscle stem cells, also known as satellite cells, is vital to
skeletal muscle regenerative capacity.1,2
Macrophages are unique effector cells in innate immunity
that play critical roles in the maintenance of tissue homeo-
stasis. Monocytes/macrophages are major inﬂammatory cell
populations recruited into injured skeletal muscle. Mouse
monocytes comprise two phenotypically distinct subsets in
blood: Ly6Chi/þ cells and Ly6Clo/ cells.3e5 Although some
groups suggest that Ly6Chi/þ monocytes are solely recruited
into injured tissue and further become Ly6Clo/ monocytes
within the tissue,3,4,6,7 others have suggested that Ly6Clo/
monocytes can also be recruited as a second wave to thestigative Pathology.
.injury site after the immediate response by Ly6Chi/þ cells.8,9
Swirski et al5 further characterized and expanded the deﬁ-
nition of Ly6Chi and Ly6Clo monocyte subsets in the blood
[speciﬁcally, CD11bþ(F480, I-Ab, CD11c)lo(CD90, B220,
CD49b, NK1.1, Ly6G)loLy6Chi/lo], which were shown to be
derived from splenic reserves and recruited to injured
myocardium following a myocardial infarction. However,
the propensity of Ly6Chi/þ and Ly6Clo/ monocytes to
differentiate into speciﬁc macrophage polarization states (ie,
M1 or M2) has not been established. Ramachandran et al6
Wang et alprovided evidence that Ly6Chi monocytes were recruited
to injured liver and further differentiated into both Ly6Chi
and Ly6Clo macrophages. Interestingly, many groups have
characterized the Ly6Chi/þ monocytes/macrophages as
proinﬂammatory, primarily by their production/expression of
proinﬂammatory cytokines/chemokines such as chemokine
ligand-2 [Ccl2, also known as monocyte chemoattractant
protein-1 (Mcp-1)],5,6 Cxcl10 [interferon-geinduced protein
10 (Ip-10)],6 inducible nitric oxide synthase (iNOS),10 tumor
necrosis factor-a (TNF-a)7,8,10,11, IL-12,10 Cxcl2 [macro-
phage inﬂammatory protein-2 (Mip-2)],3 Il-1b,3,7 and
vascular endothelial growth factor (VEGF).5 These groups
have also characterized Ly6Clo/ monocytes/macrophages as
anti-inﬂammatory by their production/expression of anti-
inﬂammatory cytokine/chemokines, growth factors, or
other markers such as Ccl22 (Mdc),3 Ccl17 (Tarc),3 Il-4,5
IL-10,5,7 transforming growth factor-b (Tgf-b),7 arginase-1
(Arg1),6,12 resistin-like alpha [Retnla, also known as found
in inﬂammatory zone-1 (Fizz-1)],6 insulin-like growth factor-
1 (Igf-1),3,6 and platelet-derived growth factor-b (Pdgf-b).3
Whereas Ly6Cþ cells have a short half-life during tissue
damage,4 Ly6C cells remain in the circulation for longer
periods and trafﬁc into peripheral tissues under noninﬂam-
matory conditions.4,13 The dynamics of Ly6Chi/þ and
Ly6Clo/ monocyte inﬁltration into injured skeletal muscle
and their propensity to contribute to proinﬂammatory and
anti-inﬂammatory macrophages in this tissue remain to be
fully explored.
Although monocytes are recruited to injured tissues,
resident macrophages also exist in tissue and play a role in
inﬂammation. Brigitte et al14 found that resident macro-
phages form a centripetal migration pathway for recruited
leukocytes by producing two chemokines, KC and MCP-1.
Two studies selectively ablated resident macrophages using
the human diphtheria toxin receptor (DTR) present on
CD11b-expressing cells (ie, monocytes/macrophages/neu-
trophils). One study showed that the intraperitoneal injec-
tion of diphtheria toxin (DT) in a CD11b-DTR mouse could
ablate resident macrophages in the kidney and ovary, but not
the hepatic sinusoidal nor alveolar macrophages.15 By using
a chimeric mouse, CD11b-DTR host with green ﬂuorescent
protein (GFP) donor bone marrow (BM), another group14
demonstrated a reduction in the resident macrophage popu-
lation in skeletal muscle with intravenous DT treatment.
Consequently, a reduction in the recruited GFPþ population
1 day after muscle injury compared to control was
observed.14 However, as the transplanted BM was GFPþ, it
is unclear whether this recruitment deﬁcit was present in the
neutrophil population (the primary myeloid cell recruited at
day 1), whether this affected macrophage recruitment at any
time points along muscle regeneration, or whether this had
any effect on the regeneration of the muscle. Regardless, the
essential role of ablation of resident macrophages in skeletal
muscle regeneration remains elusive.
The concept that macrophages are crucial in muscle re-
generation is supported by growing experimental evidence.1168Firstly, several different methods have been used to deplete
monocytes/macrophages to investigate their role in skeletal
muscle regeneration. This includes injecting antibodies
against F4/80,16 CD11b,17,18 macrophage colony-stimulating
factor (M-CSF) receptor,19 or clodronate-containing lipo-
somes1; all of these experiments demonstrated that monocyte/
macrophage depletion impaired skeletal muscle regeneration.
Secondly,mice deﬁcient inMcp-1 (also known asCcl2) or the
MCP-1 receptor, CC chemokine receptor 2 (Ccr2), demon-
strated a remarkable decrease in monocyte/macrophage
inﬁltration in association with impaired skeletal muscle
regeneration.20e24 Most importantly, the poor capacity of
skeletal muscle regeneration inCcr2/mice was restored by
transplantation with BM-derived cells fromwild-type mice.25
Thus, Ccr2 expression by BM-derived cells is critical in
skeletal muscle regeneration, an observation that strongly
supports the essential role for monocytes/macrophages in this
dynamic process.
Macrophages exhibit remarkable plasticity and are physi-
ologically diverse in response to environmental cues. Exten-
sive in vitro studies deﬁned two phenotypically different
macrophage subsets by activation state.26e29 Classically
activated, or M1 macrophages, obtained by lipopolysaccha-
ride treatment alone or in combination with IFN-g, secrete
proinﬂammatory cytokines, such as TNF-a, and increased
iNOS activity, resulting in the production of reactive oxygen
species. Alternatively activated, or M2 macrophages, are
activated by IL-4 treatment. M2 macrophages express high
Arg1, Ym1, Fizz1,12 the mannose receptor (CD206), and
CD301.2,30,31 Multiple variants based on different stimuli
have been described and designated as M2a, M2b, and
M2c,26,27 or as wound healing and regulatorymacrophages.28
Monocyte and macrophage subsets also exist in injured
skeletal muscle. Following injury, proinﬂammatory and
anti-inﬂammatory monocytes/macrophages sequentially
accumulated in muscle. Initial monocyte/macrophage pop-
ulations were associated with the production of proin-
ﬂammatory cytokines and removal of necrotic tissue. These
initial populations were replaced by monocytes/macro-
phages that were associated with the production of anti-
inﬂammatory cytokines and tissue repair.7,32 In rats, M1 and
M2 subsets were deﬁned as ED1þ and ED2þ macrophages,
respectively.33,34 Although these studies suggest that
different monocyte/macrophage subsets are associated with
different stages of skeletal muscle regeneration, the kinetics
and inﬂuence of different monocyte/macrophage subsets in
skeletal muscle regeneration remain to be determined.
DTR transgenic mice have been used to study the effects
of monocyte/macrophage ablation on tissue injury and
repair.7,15,35,36 DT binds to the heparin-binding epidermal
growth factorelike growth factor (hbEGF) receptor (also
known as DTR) followed by internalization, rapidly
inducing apoptosis in both dividing and terminally differ-
entiated cells.37 DT exhibits 1  104 less afﬁnity in normal
mouse cells compared to human cells.38 Thus, tissue-
speciﬁc transgenic expression of human hbEGF (DTR)ajp.amjpathol.org - The American Journal of Pathology
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cells, vascular smooth muscle cells, or monocytes/macro-
phages.15,39,40 CD11b-DTR mice express a transgene con-
taining a human DTR under the control of the CD11b
promoter that is constitutively expressed in monocytes and
macrophages. Ablation studies in peritoneal populations
revealed speciﬁc ablation of F4/80þ populations in CD11b-
DTR mice that were not affected when DT was injected into
wild-type mice. Additionally, other population cell numbers
such as of T cells, B cells, and granulocytes in the spleen
and peritoneal cavity were not affected by DT administra-
tion in CD11b-DTR mice.41 Therefore, monocytes/macro-
phages can be transiently and speciﬁcally ablated by
treatment with a single dose of DT.
In this study, we used DTR transgenic mice on a FVB
background (CD11b-DTR) to transiently ablate monocytes/
macrophages at different time points following injury to
investigate the effect of monocyte and macrophage subsets
on skeletal muscle regeneration. Ablating early inﬁltrating
monocytes/macrophages impaired skeletal muscle regener-
ation, whereas later ablation had a minimal effect on this
tissue response to injury.
Materials and Methods
Experimental Animals
Founder CD11b-DTR breeding mice were purchased from
Jackson Laboratory (Jackson Laboratory stock #05515; Bar
Harbor, ME) and were bred at the Audie Murphy Veterans
Hospital. Four- to 6-month-old male mice were used in this
study. All procedures complied with the National Institutes of
Health regulations and were regularly reviewed by the
institutional animal care and use committees of the Univer-
sity of Texas Health Science Center at San Antonio and the
South Texas Veterans Health Care System, San Antonio, TX.
Mouse Cardiotoxin Model
Myonecrosis was induced by the intramuscular injection of
cardiotoxin (CTX) (Calbiochem, San Diego, CA) as previ-
ously described.22 CTX destroys muscle ﬁbers but preserves
the muscle ﬁber basal lamina, nerves, blood vessels, and
satellite cells.42 In brief, two 50-mL injections of CTX (2.5
mmol/L in normal saline) were delivered uniformly into the
muscles of the right hindlimb anterior compartment; the
right hindlimb posterior compartment received four 50-mL
CTX injections. The left hindlimb was injected in a similar
manner with identical volumes of normal saline. Baseline
mice did not receive any injection and were used as con-
trols. For ﬂow cytometry experiments, mice were adminis-
tered CTX injections into both hindlimbs.
DT/Diphtheria Toxin Mutant Administration
CD11b-DTR mice were treated with DT, 15 ng/g body
weight (List Biological Laboratories, Campbell CA), byThe American Journal of Pathology - ajp.amjpathol.orgintraperitoneal injection. Control CD11b-DTR mice
received the same amount of mutated DT (DTm) (List
Biological Laboratories), which does not bind to the DTR.
For the current study, we determined the optimal dose
schedule of DT administration that could be safely used to
evaluate skeletal muscle regeneration allowing long-term
survival of the mice. Mice were divided into groups and
received one dose of DT from 15 to 35 ng/g body weight in
5 ng/g steps in dosages between groups. The higher DT
dose group (range, 20 to 35 ng/g body weight) resulted in
75% mortality at days 7 to 12 after DT injection. By
contrast, mice in the low-dose DT group (15 ng/g body
weight) had a mortality rate of 17% and could therefore be
used in experiments requiring a 21-day time point. To
determine whether multiple doses could be used, a cohort of
mice was given two to three doses of DT (10 to 15 ng/g
body weight) at least 1 week apart. Most of these mice died
at days 7 to 12. Therefore, we chose a single dose of 15 ng/g
body weight DT to ablate CD11bþ cells. These conditions
allowed for the survival of the animals through the course of
the experiment (21 days) while temporarily ablating the
monocyte/macrophage population within a speciﬁc time
frame. Previous work and our results in the kinetics of DT
ablation of monocyte/macrophage populations in multiple
tissues including regenerating skeletal muscle and blood
indicate that ablation occurs within 12 hours, lasts 24 hours,
with recovery generally occurring 48 hours after DT
administration.7,15 Single injections of DT were adminis-
tered at various times (0.5, 0, 1, 2, and 4 days) relative to
the injection of CTX to transiently ablate monocyte/mac-
rophages at different time points during skeletal muscle
regeneration.
Histology and Histomorphometry
Mice were sacriﬁced and the tibialis anterior (TA) muscles
were collected and placed in 10% neutral-buffered formalin
before routine parafﬁn embedding. For morphometric anal-
ysis, 2- to 3-mmcross sections of themid-portion of the anterior
compartment specimen were deparafﬁnized and stained with
H&E. For injury and residual necrosis assessment, slides were
scanned using a model ScanScope CS system (Aperio Tech-
nologies, Vista, CA) to create a digital image of the entire
anterior compartment for further analysis by NIS Elements
software version 3.0 (Nikon Instruments, Melville, NY).
Myoﬁber cross-sectional area, fat area (%), and capillary
density in TA muscle were determined as previously
described.20 In brief, the cross-sectional area (mm2) of myo-
ﬁbers was determined by measurement of individual myo-
ﬁbers in digitized images of a given TA muscle. Only
regenerated ﬁbers were measured in the post-CTX specimen,
whereas mature myoﬁbers with peripherally located nuclei
were measured in the baseline specimen. For morphometric
analyses, within each section, four nonoverlapping areas of
the TA muscle were digitally captured (20 magniﬁcation)
using phase contrast microscopy; areas containing large1169
Wang et alblood vessels or ﬁbrous tissue bands between muscle bundles
were excluded, and care was taken to avoid TA specimens
with tangential or longitudinal presentation of myoﬁbers. For
each histomorphometric parameter, results from all images
derived from a given section were averaged to obtain a single
value for each animal. Fat area (%) was calculated after
manual outline of the intermuscular fat area and division by
the total area of the TA image. Using digitally captured im-
ages of the entire TA in cross section, the total area of injury
for a given TA muscle was deﬁned as the area of regenerated
myoﬁbers with centrally located nuclei combined with the
area of residual necrotic myoﬁbers. Percent muscle injury
was calculated as the entire area of injury relative to the entire
cross-sectional area of TA. Percent residual necrosis was
calculated as the area of necrotic myoﬁbers relative to the
entire area of injury.
Capillary counts were evaluated after treatment of depar-
afﬁnized cross sections of TA muscle with a biotinylated
lectin, Griffonia (Banderaea) simplicifolia lectin I (Vector
Laboratories, Burlingame, CA), at dilution 1:50 followed by
streptavidin-horseradish peroxidase and incubation in dia-
minobenzidine/hydrogen peroxide to identify endothelial
cells as previously described.20 Only capillaries associated
with myoﬁbers were included and were expressed as capil-
laries per ﬁber. In addition, after subtracting the areas of fat,
ﬁbrosis, and residual necrosis from the total area, capillary
density was expressed as capillaries/mm2.
Tissue Inﬂammatory Cell Quantiﬁcation
Single-cell suspensions were prepared from muscle, BM,
spleen, and whole blood. Anterior and posterior compartment
hindlimbmuscles were harvested, minced, and enzymatically
dissociated in Hank’s balanced salt solution (Invitrogen, Life
Technologies, Grand Island, NY) supplemented with 1500
U/mL collagenase II (Invitrogen), 4.0 U/mL dispase (Invi-
trogen), and 2.5 mmol/L CaCl2 (Sigma-Aldrich, St. Louis,
MO) at 37C for 90 minutes and ﬁltered through a 40-mm
strainer (BD Bioscience, San Jose, CA) to obtain a single-cell
suspension. BM cells were obtained by ﬂushing the femur
with Hank’s balanced salt solution containing 2% fetal
bovine serum using a 25-gauge needle followed by treatment
with red blood cell lysis buffer. A single-cell suspension of
spleen cells was prepared by passingminced spleen through a
cell strainer (Falcon; Becton Dickinson, Franklin Lakes, NJ)
followed by treatment with red blood cell lysis buffer.
Approximately 1 mL of blood was obtained in a heparinized
syringe from isoﬂurane-anesthetized mice via cardiac punc-
ture, placed into a 1.3-mL EDTA KE 1.3 micro tube (Sar-
stedt, Newton, NC), transferred to a ﬂuorescence-activated
cell sorting tube (BD Bioscience) and mixed with an equal
volume of 2% dextran to sediment red blood cells for 30
minutes followed by treatment with red cell lysis buffer
(Sigma-Aldrich). All single-cell suspensions were counted
with a hemocytometer in the presence of trypan blue to obtain
total cell counts and maintained on ice until use.1170Single-cell suspensions were treated with monoclonal
antibody 2.4G2 (BD Bioscience) for 20 minutes on ice to
block Fc II/III receptors followed by incubation with con-
jugated antibodies at 4C for 30 minutes. AntieCD90-FITC
(53-2.1), antieB220-FITC (RA3-6B2), antieCD49b-FITC
(DX5), antieNK1.1-FITC (PK136), antieLy6G-PE (1A8),
antieLy6G-FITC (1A8), antieCD11b-V450 (M1/70),
antieCD11c-PE (HL3), antieI-Ab-PE (AF6-120.1), and
antieLy6C-APC (AL-21) were purchased from BD Bio-
sciences; antieF4/80-PE (BM8) was purchased from eBio-
science (San Jose, CA); antieLy6B.2-AF700 (7/4),
antieCD206-AF488 (MR5D3), and antieCD301 (ER-
MP23) were purchased from AbD Serotec (Raleigh, NC).
Isotype controls were used to titrate each antibody tominimize
background staining, 1 mg/mL propidium iodide (Sigma-
Aldrich) was used for dead cell exclusion, and ﬂuorescence-
minus-one controls were used to generate gates.43
Monocytes were identiﬁed as CD11bþ(CD90/B220/
CD49b/NK1.1/Ly6G)lo(F4/80/I-Ab/CD11c)loLy6Chi/lo as
used by Swirski et al5 to exclude neutrophils, T cells, B cells,
natural killer (NK) cells, and dendritic cells.Macrophageswere
identiﬁed as CD11bþF4/80þ cells and macrophage subsets
were identiﬁed by Ly6C, CD206, and CD301. Monocyte and
macrophage numbers were calculated as total cells multiplied
by percent cells within the monocyte/macrophage gate.
Flow Sorting of Cells to Isolate Macrophage Subtypes
Total cells that were isolated from injured muscle 3 days after
CTX were resuspended in ﬂuorescence-activated cell sorting
buffer (Hank’s balanced salt solution, 0.5% bovine serum
albumin, 2 mmol/L EDTA) with 10 mg/mL Brefeldin A
(eBioscience) and 100 mg/mL cyclohexamide (Sigma-
Aldrich) to inhibit cytokine secretion and production,
respectively. For each replicate (nZ 5), cells isolated from
the injuredmuscle of sixmicewere pooled for the experiment.
After Fc receptor blocking, cells were incubated with
antieCD11b-V450 on ice for 30 minutes followed by incu-
bation with antierat-kappa microbeads (Miltenyi Biotec,
Bergisch Gladbach, Germany). Cells were passed through a
MACSLS column (Miltenyi Biotec), and the positive fraction
(CD11bþ) was collected, washed, and incubated with
antieF4/80-PE, antieCD301-AF488, and antieLy6C-APC.
TheCD11bþ cellswere sorted on a FACSAriaﬂow cytometer
(Becton Dickinson) to collect CD11bþF4/80þLy6Cþ
CD301 and CD11bþF4/80þLy6CCD301 macrophage
cell populations. A sample of the sorted macrophages was
reanalyzed by ﬂow cytometry; purity of the sorted groups
ranged from 86% to 97%. The sorted cells were lysed in lysate
buffer (100 mL of lysate buffer per million cells).44
Intracellular Cytokine Quantiﬁcation and Arginase
Activity Assay
Sorted CD11bþF4/80þLy6CþCD301 and CD11bþF4/
80þLy6CCD301 cell populations in lysate buffer wereajp.amjpathol.org - The American Journal of Pathology
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nation in the mouse MAP panel B, a Luminex-based
multiplex platform (Rules-Based Medicine, Austin, TX);
the analytes measured included ﬁbroblast growth factor-9
(FGF-9), granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF), growth-regulated a protein (KC/GRO),
interferon-g (IFN-g), IP-10, IL-1a, IL-2, IL-3, IL-4, IL-6,
IL-7, IL-10, IL-11, IL-12p70, IL-17A, lymphotactin, MIP-
1b, MIP-2, MCP-1, MCP-3, MCP-5, oncostatin-M (OSM),
stem cell factor (SCF), T-cellespeciﬁc protein RANTES
(RANTES), tissue inhibitor of metalloproteinases-1 (TIMP-
1), TNF-a, and VEGF.
Arginase enzyme activity was determined in sorted
CD11bþF4/80þLy6CþCD301 and CD11bþF4/80þLy6C
CD301 cell populations in lysate buffer at zeroth-order
kinetics to provide a measure of arginase enzyme concen-
trations.45 Cell lysates, in the presence of excess 100 mmol/L
MnCl2 (Sigma-Aldrich), were incubated at 56C for 6
minutes to activate the arginase enzyme. The substrate, 0.5
mol/L arginine (Sigma-Aldrich), was added and incubated at
37C for 2 hours to allow for the enzymatic conversion of
arginine to urea. Urea standards (Sigma-Aldrich) were
created. An acid mixture consisting of 1:3:7 H3PO4/H2SO4/
H2O (EMD Millipore, Billerica, MA) was added to urea
standards and samples to stop the reaction. An indicator, 6%
a-isonitrosopropiophenone (a-ISPP; Sigma-Aldrich), was
added to standards and samples, and incubated at 95C for
30 minutes, followed by a 4C incubation for an additional
30 minutes. Samples and standards were read at 540 nm on
a microplate spectrophotometer.
Arginase activity was derived from the urea amount in
each sample by the equation:
ðmicrograms of urea=molecular weight of ureaÞ
 ðdilution factor=time in minutes of arginine incubationÞ:
Data were reported as units of arginase or more specif-
ically as a unit of arginase activity equals the amount of
enzyme required to hydrolyze 1 mmol/L of arginine per
minute.
Data Analysis
We contrasted DTm- and DT-treated animals with regard to
mean cross-sectional area at different time points using 2-way
analysis of variance with a Bonferroni correction and a Tukey
correction for pairwise comparisons by time within the DT
group. Corresponding treatment group contrasts with regard
to fat, injury, and necrosis were performed with Wilcoxon
tests and Bonferroni corrections for multiple comparisons.
Flow cytometry datawere analyzedwith a quadraticmodel.
We modeled the mean response of log10(total cells, mono-
cytes and monocyte subsets, macrophages and macrophage
subsets, neutrophils) with a quadratic model in terms of
method (DT, DTm), day (2, 3, 4, 5, 6), method  day, day2,
and method  day2, and contrasted mean responses by dayThe American Journal of Pathology - ajp.amjpathol.orgwith a Bonferroni correction. The method contrasts were to
determine the signiﬁcance of differences between DT- and
DTm-treated animals.
Arginase activity and cytokine data was log transformed,
and the two groups of Ly6CþCD301 and Ly6CCD301
macrophages were analyzed using a two-tailed, paired
t-test.
SAS version 9.2 for Windows (SAS Institute, Cary, NC)
was used for statistical analysis, and all statistical testing
was two-sided with an experiment-wise signiﬁcance level of
5%. Interactions were tested at the 10% level of signiﬁ-
cance. Data were presented as means  SEM.
Results
Ablation of CD11b Cells by a Single Dose of DT at
Different Time Points Has Differential Effects on
Skeletal Muscle Regeneration in CD11b-DTR Mice
We transiently ablated CD11b cells at different time points
using CD11b-DTR mice to determine essential periods for
monocyte/macrophage recruitment that were critical for
muscle regeneration (Figure 1A). TA injury was assessed at
day 7 after CTX injection. Residual necrosis, regenerated
myoﬁber cross-sectional area, and fat area are quantitative
phenotypes for muscle regeneration and indirect measures
of macrophage function. Although the muscle injury in the
TA was similar in all six groups (range, 86% to 95%), the
residual necrosis (Figure 1B) greatly varied depending on
the timing of the DT administration. DTm-injected control
mice exhibited <3% residual necrosis at day 7 after CTX
injury. However, mice that received a DT injection at days
0.5, 0, 1, or 2 exhibited progressively increasing residual
necrosis, peaking at days 1 and 2. Interestingly, late DT
administration (day 4) had similar residual necrosis as DTm
controls. Cross-sectional area of regenerated ﬁbers
(Figure 1C) and the fat area (Figure 1D) were also affected
by the timing of DT administration. Mice injected with DT
at day 1 exhibited the smallest ﬁber size, whereas mice
injected on day 0 had the highest intermuscular fat.
Early DT (Day 1) Treatment of CD11b-DTR Mice
Impaired Skeletal Muscle Regeneration
Macrophages have been implicated in muscle ﬁber matu-
ration and the resolution of inﬂammation at later stages of
regeneration,2 and this may not be measured at the day 7
time point used to screen the timing of DT administration.
Therefore, DT administration at day 1 (early) or day 4 (late)
was used to study skeletal muscle regeneration in the CTX
model (Figure 2A). Day 0 (no injury) muscle had a mature
ﬁber size of 2687  101 mm2, and intermuscular fat was not
detected. For all groups, cross-sectional area was decreased
(P < 0.001) and fat area was increased (P  0.003)
compared to day 0 at all post-injury time points. Early
macrophage ablation (day 1 DT) resulted in smaller1171
Figure 1 Time-dependent consequences of CD11b cell depletion in
skeletal muscle regeneration. TA muscle regeneration was studied in
CD11b-DTR mice and analyzed 7 days after CTX-induced injury. Timing of DT
[day 0.5 (d0.5) to day 4 (d4)] or control DTm (day 1) administration
was in reference to CTX injection (A). Although the area of muscle injury
was similar in the six groups (average of 86% to 95%), residual necrosis
(B), cross-sectional area of regenerated myoﬁbers (C), and fat area (%) (D)
at day 7 after CTX were dependent on the timing of DT administration. Data
are presented as means  SEM. nZ 7 to 10 mice/group. *P  0.04 versus
mice treated with DTm at day 1 after injury (BeD).
Wang et alregenerated myoﬁber size (Figure 2B) compared to the
DTm control (P < 0.001). Although percent fat (Figure 2C)
was similar at day 7 in all three groups, percent fat remained
elevated with early ablation but decreased in the DTm
control (P  0.003). By contrast, late ablation (day 4 DT)
exhibited similar regenerated myoﬁber size and fat accu-
mulation as the DTm control group. Capillary density,
expressed as capillaries/mm2 (Figure 2D), was increased at
day 21 (P< 0.001) compared to baseline (no injury, day 0) in
all three groups. Furthermore, early (day 1) ablation resulted
in increased (P Z 0.002) capillary density compared to the
DTm control. Finally, capillaries/ﬁber (Figure 2E) in all the
groups were similar to baseline (no injury, day 0).
Representative images of early macrophage ablation
group (day 1 DT) and control group are shown in Figure 3.
Normal myoﬁbers (Figure 3C) have a uniform size and a
polygonal shape with peripheral nuclei. Following injury,
there was a vigorous mononuclear cell inﬁltrate in DTm1172control mice at day 2 after injury (Figure 3A) that increased
by day 3. By contrast, CD11b-DTR mice receiving DT early
(day 1) exhibited minimal mononuclear cell accumulation at
days 2 and 3 (Figure 3B) with increased neutrophils
compared to DTm control mice. By day 7 after injury, DTm
control mice had small, regenerating muscle ﬁbers with
minimal necrosis (Figure 3D), whereas early DT-treated
mice had extensive necrotic muscle ﬁbers (Figure 3E).
Early DT-treated mice (Figure 3H) had smaller myoﬁbers
with more prevalent adipocytes than DTm control mice at
21 days after injury (Figure 3G). Of note, late DT-treated
(day 4) mice showed a similar phenotype compared to
DTm control mice at day 7 and day 21, respectively
(Figure 3, D and F, and G and I, respectively).
Early DT Treatment of CD11b-DTR Mice Exhibited
Diverse Effects on Total Cells and Monocytes in BM,
Blood, and Spleen
Given the impairments in muscle regeneration with early DT
treatment (Figures 2 and 3), ﬂow cytometry was used to
determine the expression pattern of monocytes, deﬁned as
CD11bþ(CD90/B220/CD49b/NK1.1/Ly6G)lo(F4/80/I-Ab/
CD11c)loLy6Chi/lo cells,5 in BM, blood, and spleen in con-
trols (DTm) and following ablation with DT treatment at day
1 after CTX injection. Day 0 (no injury) and day 1 after CTX
were used to establish monocyte patterns before ablation and
did not receive DT or DTm. Days 2 to 6 after CTX injury
were used to determine the effect of day 1 DT on monocyte
numbers compared to the DTm control (Figure 4A). With
early DT treatment, total cells (Figure 4B) in BM were
similar to controls (DTm) except for a decrease (P  0.007)
at days 2 to 3 and an increase (P< 0.001) at day 6, suggesting
that cell ablation occurred at days 2 to 3, leading to a rebound
in BM total cells at day 6. Interestingly, BM monocytes
(Figure 4E) in mice receiving DT were similar to controls at
days 2 to 3, suggesting that monocyte ablation in the BM did
not occur, but monocytes still increased (P < 0.001) in mice
receiving DT compared to controls at days 4 and 6. The
distribution of Ly6Chi (proinﬂammatory) and Ly6Clo (anti-
inﬂammatory) monocytes5 in BM (Figure 4H) revealed
similar numbers of both subtypes of monocytes in DTm
control mice. With early DT treatment, Ly6Chi monocytes
were increased (P Z 0.003) at day 6, whereas Ly6Clo
monocytes were increased (P  0.03) at days 4 and 6
compared to controls.
In blood, total cells (Figure 4C) decreased (P < 0.001) at
day 2 with early DT treatment but were similar to DTm
control groups at all other time points. Blood monocytes
(Figure 4F) were similar to day 0 throughout the time course
of injury in control mice, with decreased (P < 0.001)
monocytes in DT-treated mice at day 2 compared to controls.
The distribution of Ly6Chi and Ly6Clo monocytes (Figure 4I)
was similar in control mice throughout the injury time course.
With ablation, there were decreases (P< 0.001) compared to
controls in both Ly6Chi and Ly6Clo monocytes at day 2.ajp.amjpathol.org - The American Journal of Pathology
Figure 2 Impaired muscle regeneration with early
(day 1) DT administration compared to control DTm
and late (day 4) DT. TA muscle injury was induced in
CD11b-DTR mice and analyzed after CTX-induced injury.
Timing of DT or DTm administration was relative to CTX
injection (A). Regenerated myoﬁber cross-sectional
area (B), fat area (%) (C), capillaries/mm2 (D), and
capillaries/ﬁber (E) measurements were performed in
the TA muscle at day 0 (no injury) and after CTX-
induced injury at indicated time points. Myoﬁber size
at day 0 (no injury) was 2687  101 mm2, and inter-
muscular fat was not detected in uninjured muscle.
Data are presented as means  SEM. nZ 7 to 11 mice/
group/time point. *P  0.003 versus mice treated with
DTm at day 1 (BeD).
Macrophage Ablation Impairs RegenerationAlthough DT ablated total cells in the blood at day 2
(P < 0.001), only a portion of the ablated cells were mono-
cytes, and the recovery of blood monocytes was accom-
plished with predominately Ly6Chi cells.
In the spleen, total cells (Figure 4D) were similar in
controls and DT-ablated mice. However, splenic monocytes
(Figure 4G) increased (P  0.01) at days 5 and 6 after injury
in early DT-treated mice compared to controls. The distri-
bution of Ly6Chi and Ly6Clo monocytes (Figure 4J)
revealed similar numbers of both subtypes of monocytes in
DTm control mice. The increased (P < 0.001) monocytes at
days 5 and 6 resulted predominately from elevations in the
Ly6Chi population.
Effects of Early DT Treatment of CD11b-DTR Mice on
Muscle Inﬂammatory Cells
Given the impairment in muscle regeneration with early DT
treatment (day 1) in CD11b-DTR mice, we performed ﬂow
cytometry to quantify inﬂammatory cells in injured muscle
(Figure 5, Supplemental Table S1, and the gating strategy
shown in Supplemental Figure S1). Total cells in skeletal
muscle (Figure 5B) decreased (PZ 0.006) only at day 3 but
increased (PZ 0.001) at day 5 with DT treatment compared
to the DTm control. Neutrophils, deﬁned as CD11bþLy6Gþ
cells (Figure 5C), peaked at days 1 to 2 and rapidly
decreased thereafter in control mice compared to day 0. By
contrast, DT treatment resulted in increased (P  0.02)
neutrophils at days 3 to 6 compared to the DTm control.
Monocytes (Figure 5, D, F, and H) and macrophages
(Figure 5, E, G, and I, and Supplemental Table S1) exhibited
interesting expression patterns in injured muscle. In theThe American Journal of Pathology - ajp.amjpathol.orgcontrols relative to day 0, monocytes (Figure 5D) immedi-
ately increased and peaked at day 1 and gradually decreased.
Ly6Cþ monocytes predominated at days 1 to 2, and Ly6C
monocytes were increased at day 1 and remained at a similar
level through day 4. By contrast, early DT treatment resulted
in an exaggerated increase (P 0.04) in monocytes at days 4
and 5 compared to the control groups. The distribution of
Ly6Cþ, but not Ly6C, monocytes (Figure 5, F and H) was
affected by early DT treatment, with exaggerated increases
(P  0.02) occurring in Ly6Cþ monocytes at days 4 and 5
after injury compared to control mice.
In contrast to the sustained elevation of monocytes in
injuredmuscle, macrophages, deﬁned as CD11bþF4/80þ cells
(Figure 5E and Supplemental Table S1), increased after injury,
with peak numbers occurring at day 4 in the control mice.
Early DT resulted in decreased (P  0.03) macrophages at
days 2, 3, and 4 compared to controls, leading to delayed and
reduced macrophages. Although macrophages after day 4
were similar in DT and control groups, no distinct peak was
observed in DT-treated animals. To further characterize
macrophage subsets, we used Ly6C, CD206, and CD301
for further phenotypic analysis of the CD11bþF4/80þ cell
populations (Supplemental Figure S1). CD206 and CD301
were coexpressed on macrophages and exhibited similar
results when combined with Ly6C (data not shown),
CD301 expression data are shown (Figure 5, G and I). The
main macrophage subsets in both the control group and
early ablation group were Ly6Cþ cells or Ly6CCD301
double-negative cells. There was minimal CD301 expres-
sion among all groups. In the control group following injury
(Figure 5, G and I), the Ly6CþCD301macrophage subset
predominated at days 1 to 3 and was minimal by day 6. By1173
Figure 3 Inﬂammation, myoﬁber necrosis, and tissue regeneration in TA muscle following CTX-induced injury in CD11b-DTR mice after administration of DT
or DTm control. Images were derived from TA muscle of CD11b-DTR mice. Control mice received DTm (A, D, and G) and were sacriﬁced at the indicated time
point after CTX injection [day 2 (2d), 7, or 21 CTX]. DT was administered at day 1 after CTX (B, E, and H) or day 4 after CTX (F and I). Thus, specimens were
derived at day 0 (no injury, baseline) (C), 2 (A and B), 7 (DeF), or 21 (GeI) days after CTX-injury. Asterisks identify necrotic muscle ﬁbers; arrows indicate
neutrophils, parafﬁn sections (3e4 mm), hematoxylin and eosin stain.
Wang et alcontrast, the double-negative (Ly6CCD301) macrophage
subset was themain cell population at days 3 to 6with a peak at
day 4 and a sustained presence at days 5 and 6. Early CD11b-
positive cell ablation drastically reduced (P < 0.001) the
Ly6CþCD301 macrophage subset at day 2, resulting in a
delayed accumulation of Ly6CþCD301 compared to con-
trols, thus DT treatment shifted, but did not decrease,
Ly6CþCD301 macrophage accumulation. In parallel, the
Ly6CCD301 macrophages were decreased (P  0.02) at
days 2, 3, and 4 compared to controls, and became the pre-
dominant cell population at days 5 and 6. Although DT
treatment shifted the accumulation of both Ly6CþCD301
and Ly6CCD301 macrophages, the double-negative
(Ly6CCD301) macrophage population demonstrated an
overall decreased accumulation in DT-treated mice, never
reaching the peak levels observed in control mice.
Characterization of CD11bþF4/80þ Macrophage
Subsets in Muscle
To further characterize the Ly6CþCD301 and the double-
negative (Ly6CCD301) population, cytokine expression
in sorted cells was determined. Many cytokines and1174chemokines associated with M1 macrophages (IL-1a,46,47
MCP-14851, MCP-3,50,51 MIP-2,3 OSM,52 TNFa,7,47,49,53
and VEGF5,54) exhibited increased (P  0.05) expression
in the Ly6CþCD301 macrophage population relative to the
double-negative population (Figure 6, B, DeG, I, and J).
Other cytokines that have not previously been associated
with the M1 population (FGF-9, lymphotactin, and SCF)
were also increased (P  0.04) in the Ly6CþCD301
population relative to the double-negative population
(Figure 6, A, C, and H). Additionally, arginase activity
(Figure 6K) was higher in the double-negative population
(P Z 0.02) than in the Ly6CþCD301 macrophages.Discussion
The present study investigated monocyte/macrophage sub-
sets in skeletal muscle regeneration by transiently ablating
monocytes/macrophages at different time points after injury
in CD11b-DTR mice. Early monocyte/macrophage ablation
by a single DT treatment altered the phenotypic switch of
macrophage subsets and impaired muscle regeneration.
However, late monocyte/macrophage ablation had minimalajp.amjpathol.org - The American Journal of Pathology
Figure 4 Diverse effects of early DT treatment on total cells and monocytes in BM, blood, and spleen. Timeline of CTX and DT/DTm injections and ﬂow
cytometry (A). Hatched bars (BeG) are cell counts per gram of tissue from uninjured (day 0) and injured (day 1) mice that did not receive DT or DTm (control)
injections. BM (B, E, and H), blood (C, F, and I), and spleen (D, G, and J) were collected for ﬂow cytometry analysis. Results are provided as total cells (BeD),
monocytes (CD11bþ(CD90/B220/CD49b/NK1.1/Ly6G)lo(F4/80/I-Ab/CD11c)loLy6Chi/lo) (EeG), and monocyte subsets (Ly6Chi or Ly6Clo) (HeJ). Data are
means  SEM. n Z 4 to 6 mice/group/time point. *P  0.01 versus DTm controls at each corresponding time point (B, C, and EeG); yP  0.003 Ly6Chi
monocytes in DT- versus DTm-treated animals at each corresponding time point (HeJ); and zP  0.03 Ly6Clo monocytes in DT- versus DTm-treated animals at
each corresponding time point (H and I).
Macrophage Ablation Impairs Regenerationeffect on skeletal muscle regeneration. Our results suggest
that the ratio of Ly6Cþ and Ly6C macrophages, and their
temporal expression, is critical in muscle regeneration.
Macrophages play a critical role during healing/regener-
ation processes,1,7,55 both in removing necrotic tissue and
promoting repair.8,56 In muscle, Ly6Cþ monocytes/macro-
phages predominated at early time points after injury and
exhibited a proinﬂammatory proﬁle, whereas Ly6C mono-
cytes/macrophages were the main cell population with anThe American Journal of Pathology - ajp.amjpathol.organti-inﬂammatory proﬁle at later stages of regeneration.7,55
However, both of these studies quantiﬁed the combination
of monocytes and macrophages rather than dividing mono-
cytes and macrophages into distinct groups. CD11b-DTR
transgenic mice have been widely used for monocyte/
macrophage ablation.7,15,35,36,57e59 DT-induced ablation,
demonstrated by our data and previous reports,7,41 is effective
for approximately 2 days. We transiently ablated various
monocyte/macrophage populations by treating CD11b-DTR1175
Wang et almice with a single dose of DT at different time points to
investigate the kinetics of Ly6Cþ and Ly6C monocytes as
well as macrophages in skeletal muscle regeneration. We
used day 7 after injury to determine the effect of monocyte/Figure 5 Effect of ablation on accumulation of inﬂammatory cells in injured m
DTm or DT treatment on day 1. Inﬂammatory cells were analyzed by ﬂow cytometry
and the ﬁrst two data sets in (F and G) are cell counts per gram of tissue from u
(control) injections. Results are provided as total cells (B), neutrophils (CD11bþ/
Ab/CD11c)Ly6Cþ/) (D), monocyte subsets (F and H), macrophages (CD11bþ
means  SEM. nZ 4 to 6 mice/group/time point. *P  0.04 versus DTm animals a
DTm animals at each corresponding time point (H); zP < 0.001 Ly6CþCD301
xP  0.02 Ly6CCD301 macrophages versus DTm animals at each corresponding
1176macrophage ablation at various time points for differences in
residual necrosis, fat accumulation, and regenerated ﬁber
size. Although DT treatment on CD11b-DTR mice at days 0,
1, and 2 resulted in increased residual necrosis at day 7, onlyuscle. Muscle was injured with CTX on day 0 in CD11b-DTR mice followed by
at day 0 (no injury) and each day after CTX injury (A). Hatched bars (BeE)
ninjured (day 0) and injured (day 1) mice that did not receive DT or DTm
Ly6Gþ) (C), monocytes (CD11bþ(CD90/B220/CD49/NK1.1/Ly6G)(F4/80/I-
F4/80þ) (E), and macrophage subsets (G and I). Data are presented as
t each corresponding time point (BeE); yP  0.02 Ly6Cþ monocytes versus
macrophages versus DTm animals at each corresponding time point; and
time point (I).
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Macrophage Ablation Impairs Regenerationmice with DT treatment at days 1 and 2 exhibited smaller
regenerated ﬁbers. Interestingly, mice with DT treatment at
day 0 showed an increase in fat accumulation (Figure 1),
suggesting that the microenvironment in injured muscle at
day 0 may have an effect on the proliferation and differenti-
ation of adipogenic progenitor cells in muscle, whereas the
monocyte/macrophage-induced microenvironment at day 1
preferentially affected myogenic progenitor cells. Neverthe-
less, although fat accumulation was similar in early ablation,
compared to late ablation and controls at day 7, fat accumu-
lation remained elevated at day 21 after early ablation,
whereas it decreased in late ablation and control groups
(Figure 2C), suggesting that events regulated by monocytes/
macrophages at early time points alter the long-term course of
fat accumulation.
Increased fat accumulation in muscle, in association with
decreased macrophages recruitment, has also been observed
in Ccr2/ mice in several different muscle injury
models,20,22,60, and increased fat accumulation maybe an
indicator of abnormal/altered muscle regeneration. Two
studies demonstrated that accumulated adipocytes origi-
nated from ﬁbrocyte/adiopocytes progenitors (FAP) that
reside in skeletal muscle61,62 rather than from myogenic
progenitor cells. FAP enhance proliferation and differenti-
ation of myogenic progenitors but do not generate myo-
ﬁbers. During homeostasis and regeneration, FAP remain in
an undifferentiated state due to inhibition signals from
muscle lineage cells. After muscle injury, FAP differentiate
into adipocytes and ﬁbroblasts, which may inhibit the acti-
vation of muscle progenitor cells. Altogether, increased fat
accumulation in skeletal muscle maybe due to FAP differ-
entiation into adipocytes secondary to the absence of signals
provided by the early inﬁltrating monocytes/macrophages.
In addition to muscle regeneration, macrophages are
also important in angiogenesis, which is essential for estab-
lishing capillary networks necessary for muscle regenera-
tion.63,64 Our previous work demonstrated maximal capillary
density (capillaries/mm2) was present at day 7 after injury in
C57BL/6J mice and decreased thereafter, returning to base-
line levels by day 28.22 In this study, we measured angio-
genesis using capillary density at days 0 and 21.Angiogenesis
could not be quantiﬁed at day 7 after injury in CD11b-DTR
mice because of extensive residual necrosis. Thus, the
increased capillaries/mm2 in the early ablation group at day 21
compared to day 0, which was not observed in the DTm
control and late ablation groups at day 21, suggests that the
return to baseline capillary density may have been delayed by
early macrophage ablation (Figure 2). Alternatively,
increased capillaries/mm2 in the early ablation group at day 21
could have resulted from the delayed, but sustained, presence
of Ly6Cþ macrophages (Figure 5, G and I), which is consis-
tent with Willenborg et al54 showing that Ly6CþCD11bþF4/
80þ macrophages were the main source of VEGF; a critical
factor in initiating vascularization during wound healing.
In addition to the changes in fat accumulation and
capillary density, early, but not late, ablation, resulted in aThe American Journal of Pathology - ajp.amjpathol.orgsmaller regenerated ﬁber size compared to DTm controls,
which is consistent with a previous study.7 A possible
explanation is that DT treatment only ablates circulating
monocytes, but not monocytes/macrophages that were pre-
sent in muscle at the time of DT administration. Further
support for this possibility derives from Arnold et al’s7
intravenous injection of DT at day 4 after muscle injury
that did not alter either F4/80þ or CD11bþ cells isolated
from muscle. However, intramuscular injection of DT at day
5 resulted in decreased F4/80þ cells with a twofold increase
in CD45þ cells at day 6 versus PBS-injected muscle, sug-
gesting that intramuscular injection of DT induced a sec-
ondary inﬂammatory response in muscle that consisted of
cells other than macrophages. Taken together, these data
support the notion that the intramuscular injection of DT is
necessary to ablate macrophages that are already present in
the muscle, whereas intraperitoneal and intravenous DT
injection ablates circulating monocytes.
Given the differences in capillary density, regenerated
ﬁber size, and fat accumulation with early ablation, detailed
ﬂow cytometry studies were performed to determine the
kinetics of inﬂammatory cell recruitment in early-ablated
mice and controls. Neutrophils are key players in early
inﬂammation, but the continued presence of neutrophils can
extend muscle injury and membrane damage.65e67 Persis-
tence of neutrophils in injured tissue may reﬂect a reduction
in macrophage-mediated neutrophil clearance.68,69 In this
study, monocytes and macrophages were transiently ablated
in skeletal muscle; however, CD11bþLy6Gþ neutrophils, a
myeloid cell population that were also expected to be ab-
lated in muscle, remained elevated in early DT-treated mice
compared to control mice (Figure 5C), which is consistent
with previous observations.35,36 A possible explanation is
that neutrophils have a lower density of CD11b compared to
monocytes/macrophages, which may protect neutrophils
from ablation in DTR mice.15,41 Alternatively, DT admin-
istration may affect recruitment to injured muscle, but may
not result in ablation of neutrophils that were already present
in muscle at day 1 after injury. Further studies are needed to
determine the potential mechanisms of the persistent ele-
vations of neutrophils after early ablation.
To determine monocyte kinetics, we studied the effects of
early ablation on monocytes in BM, blood, spleen, and
muscle. In response to injury, monocytes are released from
BM to blood, enter injured tissue, and differentiate into
macrophages.70,71 In addition to BM, the spleen has been
identiﬁed as a reservoir for monocytes that exhibit a similar
phenotype as blood monocytes.5,71 In a myocardial infarction
model, monocytes decreased in the spleen and increased in
injured tissue. However, the number of monocytes in BM
remained similar, suggesting that spleen was the primary
reservoir, rather than BM, for monocytes mobilized to
injured tissue.5 By contrast, in control mice in the skeletal
muscle injury model, monocytes in BM increased at days 1 to
2 after injury (Figure 4E), whereas monocytes in blood and





Figure 6 Characterization of CD11bþF4/80þ macrophage subsets. Ly6CþCD301 and Ly6CCD301 macrophages (CD11bþF4/80þ) were sorted from CTX-
injured muscle at day 3. Sorted cells were lysed with lysate buffer, and the lysates were used for measuring the concentrations of cytokines (AeJ) using a
bead-based multiplexing immunoassay. Measured analytes that were not signiﬁcantly different between the macrophage subsets or below the level of detection
included GM-CSF, KC-GRO, IFNg, IL-2, IL-3, IL-4, IL-6, IL-7, IL-10, IL-11, IL-12p70, IL-17A, IP-10, MCP-5, MIP-1b, RANTES, and TIMP-1. Lysates were also used to
determine arginase activity (K). Data are presented as means SEM. nZ 4 to 5; cells isolated from the skeletal muscles of six mice were pooled for each replicate.
*P  0.05 cytokines in Ly6CþCD301 versus Ly6CCD301 cells (AeI), for arginase activity; yPZ 0.02 Ly6CþCD301 versus Ly6CCD301 cells (K).
Wang et al
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Macrophage Ablation Impairs RegenerationG). These observations suggest that the monocyte elevations
in muscle after injury (Figure 5D) may have emanated from
the BM. Interesting patterns emerged with ablation; blood
monocytes (Figure 4F) were ablated at day 2, but monocytes
in BM and spleen were similar to controls at day 2. In fact,
monocytes exhibited an exaggerated increase at day 4 in the
BM, but at day 5 in the spleen, compared to control mice,
suggesting that the precedent increase in BMmonocytes may
have been the source of the increase 1 day later in spleen.
Although we used the same antigens to deﬁne monocytes as
the cardiac ischemia model,8 our results differed. Possible
explanations for the differences in the two studies include
cardiac versus skeletal muscle injury, as well as different
mouse strains of C57Bl/6J versus FVB used.
Differences also existed in the monocyte kinetics in the
BM and splenic compartments, the sequential expression/
recruitment of Ly6Cþ and Ly6C monocytes in injured
muscle was different from the cardiac ischemia model.8 In
control mice, muscle total monocytes increased at day 1 and
gradually decreased (Figure 5D). However, Ly6Cþ mono-
cytes predominated at early stages (days 1 to 3), and Ly6C
monocytes were increased at day 1 and remained at a similar
level through day 4. With ablation, Ly6Cþ monocytes
showed a similar, but delayed, expression pattern compared
to control mice, with increases in Ly6Cþ monocytes occur-
ring at days 4 and 5 in muscle (Figure 5, F and H). Although
these two monocyte populations appeared in tissue after
injury in control mice, the mechanisms that control the
Ly6Cþ/Ly6C monocyte ratio are injury and tissue depen-
dent. In a myocardial infarct model, Ly6Chi and Ly6Clo
subsets were sequentially recruited using different chemokine
pathways, MCP-1 essential for Ly6Chi monocyte recruitment
and CXC3CL1 essential for Ly6Clo recruitment.5,8 A
possible explanation in our model is that in the context of the
microenvironment provided by early DT treatment, chemo-
kines such as MCP-1 and CX3CL1 that are expressed in
injured muscle may also have been altered, resulting in the
recruitment of both Ly6Cþ and Ly6C monocytes.
In addition to investigating the kinetics of monocyte sub-
sets in injured muscle, we also explored the kinetics of
macrophage subsets. To our knowledge, this is the ﬁrst study
that determined the kinetics of the well-characterized mono-
cyte and macrophage subsets in muscle tissue and their roles
in muscle regeneration after ablation. The study by Arnold
et al7 used Cx3cr1gfp/þ mice, and after muscle injury,
the initial CX3CR1loLy6Cþ cells switched to the
CX3CR1hiLy6C population. Brechot et al55 used F4/80 and
Ly6C combinations. Both of these studies used surface
markers that represented a mixed population of monocytes
and macrophages. A third study focused on the kinetics of
CD45þF4/80þ macrophages and their Ly6Cþ and Ly6C
subsets in muscle regeneration and did not determine mono-
cyte kinetics.72 We took advantage of selective and transient
monocyte/macrophage ablation in CD11b-DTR mice, rather
than achieving only partial ablation for an extended time
after injury as used in previous macrophage depletionThe American Journal of Pathology - ajp.amjpathol.orgstudies.1,16e19More importantly, as shown in Figure 5, G and
I, early ablation resulted in a delayed Ly6CþCD11bþF4/80þ
macrophage accumulation in muscle, which was accompa-
nied by a delayed and decreased accumulation of Ly6C
CD11bþF4/80þ macrophages compared to control mice.
Our study suggests that the timing and magnitude of
Ly6CCD11bþF4/80þ macrophages is dependent on the
duration and timing of the Ly6CþCD11bþF4/80þ macro-
phages, and the disordered accumulation of macrophage
subsets by early DT treatment impaired skeletal muscle
regeneration; these results are consistent with a previous
observation.72
Studying monocyte and macrophage populations in
muscle regeneration, and the effect of early ablation, led to
several interesting observations. Blood monocytes remained
remarkably constant, with similar numbers at baseline and
all post-injury time points, with roughly equal numbers of
Ly6Chi and Ly6Clo monocytes. At day 1 after injury in
muscle, monocytes (1  106 cells/g) predominated, and
relatively few macrophages were present, with the numbers
of monocytes gradually decreasing thereafter, suggesting
that recruited monocytes differentiated into macrophages in
tissue. By contrast, few macrophages were present at day 1,
but rapidly increased to approximately 3 to 4  106 cells/g
at days 3 and 4 and decreased to approximately 1.5  106
cells/g thereafter. Similar to monocytes, Ly6Cþ macro-
phages peaked at early time points, but the majority of
macrophages at days 3 to 6 were Ly6C. Given the relative
numbers of monocytes and macrophages within injured
muscle, questions arise regarding monocyte-to-macrophage
differentiation, as well as recruitment versus proliferation
within the injured tissue. Macrophages can proliferate in
tissues.73 The relatively lower numbers of monocytes in
injured muscle compared to macrophages, and the transient,
but greater, magnitude increases in macrophages, suggest
that macrophage proliferation occurred in muscle. However,
the relative contributions of monocyte/macrophage recruit-
ment versus proliferation remain to be determined.
With early ablation, monocytes decreased at day 2 in
blood, but not in muscle, BM, or spleen. Of note, exag-
gerated increases in monocytes in muscle at days 4 to 5 and
in spleen at days 5 and 6 may have derived from the
increased monocytes in the BM at day 4. By contrast,
muscle macrophages were decreased with early ablation at
days 2 to 4, reaching levels of almost 3  106 cells/g at day
5, but never attaining the approximately 4  106 cells/g
attained in control mice. Ablation resulted in a delay, but
with similar numbers of Ly6Cþ macrophages compared to
controls, however; Ly6C macrophages remained decreased
compared to controls, thereby leading to altered ratios of
Ly6Cþ and Ly6C macrophages with ablation that may
have affected muscle regeneration. Interestingly, the exag-
gerated increase in muscle monocytes at days 4 and 5 in
ablated animals did not result in macrophage levels being
similar to control animals, suggesting that the increased
monocytes could not compensate for the decreased1179
Wang et almacrophages in ablated mice in regard to removing necrotic
tissue and enhancing regenerated myoﬁber cross-sectional
area (Figure 1). Thus, alterations in monocyte recruitment
and reductions in the Ly6C macrophage subset were
associated with impaired muscle regeneration. Because
these events occurred with early DT ablation, it is not fully
evident which cellular event, surge of monocytes at days 4
and 5 or depletion of macrophages and altered subtype
distribution on recovery, was the predominant cause of the
impair muscle regeneration phenotype. However, we have
explored monocyte/macrophage recruitment-deﬁcient
models of impaired skeletal muscle regeneration such as
the Ccr2/ mice.22 The impaired regeneration phenotype
was very similar to the early DT-ablated CD11b-DTR
mouse; however, the monocyte surge did not occur, sug-
gesting the essential cellular event was macrophage abla-
tion, an attribute shared by both models.
Further support for the beneﬁcial role of Ly6C mono-
cytes/macrophages and the importance of the orderly
macrophage subtype transition in muscle regeneration has
been described in several publications. Thrombospondin-1
(Tsp1) regulates the release of proinﬂammatory and anti-
inﬂammatory cytokines,74 and was highly expressed dur-
ing various models of tissue injury.75,76 In a hindlimb
ischemia model, Tsp1/ mice recruited similar numbers of
total macrophages, but had an increased ratio of Ly6C to
Ly6Cþ macrophages, resulting in decreased necrosis with
increased angiogenesis and muscle regeneration compared
to controls.55 Mitogen-activated protein kinase phosphatase-
1 (MKP-1), a negative regulator of MAPKs (p38 and
JNK),77 plays a role in muscle regeneration78 and innate
immunity.79 Loss of MKP-1 deregulated the timely transi-
tion of macrophage from a proinﬂammatory Ly6Cþ to anti-
inﬂammatory Ly6C state, resulting in impaired muscle
regeneration, suggesting that orchestrated macrophage-
phenotype transition controlled by MKP-1 is critical to
muscle regeneration.72 Other compelling evidence for the
essential role of anti-inﬂammatory macrophages has been
provided by a mouse model with deletion of two cAMP
response element-binding (CREB)-binding sites from the
CCAAT/enhancer-binding protein beta (Cebpb) promoter.
Although the macrophage recruitment and proinﬂam-
matory macrophage gene phenotype were normal, anti-
inﬂammatory macrophage polarization was defective,
evidenced by a failure of induction of the M2-speciﬁc gene
Arg1. Mice with the mutated Cebpb promoter removed
necrotic muscle but had severe defects in muscle ﬁber
regeneration.12 Lu et al23 reported diminished Ly6Cþ and
Ly6C populations in injured skeletal muscle of Ccl2/
mice and that muscle macrophages exhibited diminished
IGF-1 expression at day 3 following injury in Ccl2/
compared to wild-type mice. Supplementation of IGF-1
in vivo at day 3 recovered skeletal muscle regeneration in
Ccl2/ mice. It is possible that IGF-1 deﬁciency, poten-
tially due to the decrease in Ly6CCD301 cells in ablated
mice, was one of the factors in the impaired muscle1180regeneration present in our model. These results support
the essential role of the anti-inﬂammatory Ly6C macro-
phages in skeletal muscle regeneration.
Although CD301 and CD206 are widely used as M2
surface markers in other tissue,80,81 minimal expression of
CD301 and CD206 was present on the CD11bþF4/80þ
macrophages as well as other noninﬂammatory cells in
muscle, as previously reported.82 Surface markers for
macrophage subsets can vary with the injury model and
tissue being studied. Approximately 10% to 15% of the cells
isolated from muscle were CD301þ and CD206þ, with
many of these cells (60% to 97%, depending on time point)
being negative for CD11b (data not shown). The antibodies
for CD206 and CD301 exhibited high expression in
in vitroepolarized BM-derived macrophages exposed to
IL-4 (data not shown), thus it is unlikely that the antibodies
did not recognize the antigens in injured skeletal muscle. In
addition, CD206 can be regulated by tissue microenviron-
ment83 and hormones.84 For example, dermal mononuclear
cells exhibited an increased surface expression of CD206 on
migration to lymph nodes or cultured with conditioned
medium from skin-explant culture.83 Li et al84 demonstrated
that female mice exhibited enhanced surface expression of
CD301 in Coxsackievirus B3einduced myocarditis,
whereas male mice showed minimal surface expression,
which may account for the minimal surface expression of
these two markers in the male CD11b-DTR mice used in
this study. Lin et al3 demonstrated that although Ly6Chi and
Ly6Clo ﬂow-sorted kidney macrophages exhibited equiva-
lent surface expression of CD206, the Ly6Chi population
expressed high levels of the M1-associated cytokine
mRNAs Mip-2 and Il-1b, and the Ly6Clo population
expressed M2-associated mRNAs Igf-1, Ccl17, Ccl22, and
Pdgf-b. In contrast to the relative paucity of CD301 in our
system, the Ly6CCD301 population exhibited arginase
activity consistent with M2 macrophages in vitro. Recent
in vitro studies suggest that arginase as a marker of M2
macrophages is context-dependent and that other pathways
independent of the M2-related STAT6 activation can also
promote the expression of arginase.85e89 However, in the
context of regenerating skeletal muscle, the utility of argi-
nase in characterizing M2-like macrophages has been
established. A recent study by Mounier et al90 showed that
loss of function of Ampka1 in skeletal muscle resulted in a
defect of acquiring a M2 phenotype, and the Ampka1/
mice exhibited a decreased number of M2 marker arginase-
positive cells; the number of other M2 marker (TGFb,
CD206, CD163) positive cells were increased in Ampka1/
mice. Additional evidence emanates from Cebpb promoter
mutated mice that had impaired skeletal muscle regeneration.
Macrophages in vitro from these mice exhibited a defect in
M2 macrophage-speciﬁc gene expression (Msr1, Il10, Il13ra,
and Arg1), but in the animal during skeletal muscle regen-
eration, the evidence of a defect in M2 polarization was
evident by a diminished Arg1 expression only.12 We char-
acterized the Ly6CþCD301 population as proinﬂammatoryajp.amjpathol.org - The American Journal of Pathology
Macrophage Ablation Impairs Regenerationbased on the cytokine and chemokines production anticipated
from M1 macrophages such as IL-1a,46,47 MCP-1,4851
MCP-3,50,51 MIP-2,3 OSM,52 TNFa,7,47,49,53 and VEGF.5,54
The additional cytokines that were signiﬁcantly elevated in
the Ly6CþCD301 (FGF9, lymphotactin, and SCF) are not
commonly associated with M1 macrophages. However, we
conﬁrmed that these three cytokines were expressed at higher
levels in the cell culture supernatants of IFNg þ lip-
opolysaccharideestimulated BM-derived macrophages rela-
tive to control, IL-4estimulated, and IL-10estimulated
BM-derived macrophages (unpublished data). These ﬁnd-
ings are consistent with previous work that deﬁned Ly6Cþ
macrophages as proinﬂammatory and Ly6C macrophages
as anti-inﬂammatory based on cytokine production and
arginase activity.3,5,8,10
IL-4 and IL-10 are important cytokines that are associated
with M2macrophages. For example, eosinophil-derived IL-4
in adipose tissue can sustain M2 macrophages to maintain
glucose homeostasis.91 In skeletal muscle, IL-4 secreted by
eosinophils stimulated FAPs instead of macrophages to pro-
mote skeletal muscle regeneration.92 IL-4 was not detected in
our sorted macrophage populations, which may be explained
by eosinophils providing the main source of IL-4. In addition,
IL-10, a context-dependent cytokine,88,93 exhibited compa-
rable expression in both Ly6Cþ and Ly6C macrophages,
which is consistent with the studies performed in liver and
kidney injury models.3,6 All these ﬁndings suggest that
translation of the markers of macrophage heterogeneity
identiﬁed from in vitro to in vivo studies is challenging.
In conclusion, the present study deﬁned time points when
ablating monocytes/macrophages resulted in an impaired
muscle regeneration phenotype. Early ablation (days 0 to 2)
resulted in themost severe impairments, whereas late ablation
(day 4) had minimal effects. Arnold et al7 established the
patterns of Ly6Cþ/CX3CR1hi and Ly6C/CX3CR1lo
monocyte/macrophage subset dynamics during skeletal
muscle regeneration; however, the effects that early ablation
has on the distribution of thesemonocyte/macrophage subsets
has not been explored. Comprehensive proﬁling ofmonocyte/
macrophage recruitment with early ablation suggested that
monocytes recruited to injured muscle contained both Ly6Cþ
and Ly6C populations. We explored the dynamics of
monocytes both in number and in distribution of Ly6C pop-
ulations in the BM, spleen, and blood during skeletal muscle
regeneration. Our studies sought to extend the deﬁnition of
macrophage subsets by investigating M2 macrophage
markers (CD301 and CD206) and their relation to the Ly6C
populations but discovered in our model of skeletal muscle
regeneration that few macrophages were positive for CD301
or CD206. Macrophages were sequentially expressed as
Ly6CþCD301 or double-negative cells. Ablation resulted in
exaggerated monocyte recruitment and reduction in double-
negative macrophages that did not attain the peak levels
present in DTm control mice. To conﬁrm that the double-
negative macrophages represented an anti-inﬂammatory
subtype, cytokine production and arginase activity wereThe American Journal of Pathology - ajp.amjpathol.orgdetermined and provided evidence of a M2-like phenotype.
The switch of macrophage subsets appears to be critical to
skeletal muscle regeneration. Additional studies are required
to deﬁne the precise mechanisms that control the switch of
macrophage subsets, which may be used as potential thera-
peutic approach to promote skeletal muscle regeneration.
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